Prevenar (Wyeth) — Competitive Intelligence Brief

Prevenar (Wyeth) (Prevenar (Wyeth)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide antigens Immunology / Infectious Disease Biologic

Target snapshot

Prevenar (Wyeth) (Prevenar (Wyeth)) — GlaxoSmithKline. Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prevenar (Wyeth) TARGET	Prevenar (Wyeth)	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens
GSK1024850A (SynflorixTM)	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
GSK1024850A (Synflorix)	GSK1024850A (Synflorix)	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
20vPCV	20vPCV	Sanofi Pasteur, a Sanofi Company	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (20 serotypes)
Prevnar (PCV7)	Prevnar (PCV7)	University of Minnesota	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F)
Prevenar 13 and Synflorix	Prevenar 13 and Synflorix	Papua New Guinea Institute of Medical Research	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotype-specific)
PCV 20	PCV 20	Inventprise Inc.	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (20 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pneumococcal conjugate vaccine class)

1. GlaxoSmithKline · 12 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Korea University Guro Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. Papua New Guinea Institute of Medical Research · 1 drug in this class
6. Pfizer Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. University of Oxford · 1 drug in this class
10. Vabiotech · 1 drug in this class